CellCelector - Single Cell, Colony or Organoid Selection and Retrieval’s Post

Let's start a daily challenge to celebrate advances and good news in the cell and gene therapy space! 🎯 Aim: 1 post a day to celebrate new scientific advances, partnerships, investments, etc in cell and gene therapies and spread some positivity :) Day 1: Astellas Pharma and Poseida Therapeutics, Inc. enter into research collaboration and license agreement to develop off-the-shelf CAR-Ts for solid tumors. Combining Poseida's allogeneic technology and Xyphos' novel convertibleCAR™ approach, the collaboration aims to create flexible off-the-shelf cell therapies that can be "engineered and re-engineered inside the body to target more than one tumor antigen". Congratulations! #CGT #allogeneic #celltherapies #celebrate #monthofCGTcelebrations

Sign up for this upcoming webinar on September 24th: Comparing activation methods to yield clinical-scale expansion of γδ #Tcells. Some #Tcelltherapies have been approved to treat patients with conditions like #Bcellmalignancies and #multiplemyeloma, but their use for #solidtumors remains challenging. Gamma delta (γδ) T cells have the inherent ability to infiltrate solid tumors and kill transformed cells, but their low prevalence in peripheral blood poses a challenge when generating enough cells to produce a clinical dose. Join this webinar, hosted by Cell & Gene Therapy Insights, in which our colleague Chengkang Zhang (Associate Director, R&D, Lonza) will present two novel methods for the expansion of #gammadeltaTcells from peripheral blood #mononuclearcells (PBMCs) and present data showcasing their suitability for clinical applications.   Register now and take the chance to pose any questions you may have about gamma delta T cell expansion during the live Q+A session: https://lnkd.in/e6dbeGhf

Next week, our Head of Cell Therapy, Melissa Van Pel, will speak at Advanced Therapies 2024 on "Advances in Cell and Gene Therapies: Process Development and Future Perspectives." In her presentation, Melissa discusses the potential of Cell and Gene therapies to deliver long-term solutions to patients worldwide. She will share her expertise on cell therapy manufacturing, emphasising the shift from open to closed processes, the challenges of scaling up to bioreactors, and the importance of maintaining product quality through rigorous process development. If you're attending, make sure to join the discussion on the advancements in cell therapy, including the evolution towards automation, the utilisation of bioreactors for cell expansion, and the ongoing transition from autologous to allogeneic therapies. These innovations promise to enhance the scalability and efficacy of treatments and aim to make them more accessible by reducing costs and increasing production capacities. Would you like to get more from your visit by discussing CGT challenges with Melissa? Start a conversation with our BD Tristan Pritchard-Meaker, Sophia Kolbe, and André Soares! #CGT #celltherapy #genetherapy

While 2023 was the year of gene therapy, 2024 is already shaping up to be the year of cell therapy. Today, we have released our April 2024 Sector Snapshot, which focuses on recent key advancements propelling engineered cell therapies. In this edition, you will find:   📋 An updated 2024 clinical pipeline outlook 🔬 Review of the cell therapy clinical landscape 🧫 Trends driving cell therapy development Read it here: https://lnkd.in/exkeE8bJ #Celltherapy #Oncology

What do you do with your iQue®️ High-Throughput Screening (HTS) by Cytometry Platform? ✅ Have your published papers been included in this publications list? Use this web page tool to search for iQue®️ HTS users’ papers. More papers will be added over time. Bookmark and periodically visit this page. ✅ Discover the published papers of some other researchers in antibody discovery, cytotoxicity, neuroscience, drug discovery, cell therapy, gene therapy, immuno-oncology and infectious diseases. Check out publications here: https://ow.ly/j3vw50SCXW0 #cellhealth #cytokine #celltherapy #genetherapy #cellandgenetherapy #highthroughputscreening #lifescience #research #iQue

I was in Barcelona last week for the 7th Annual Cell & Gene Therapy Innovation Summit, where I had the opportunity to talk about the importance of bringing the potential of cell therapy to more people living with cancer. This topic is especially critical today, as we know that only a fraction of eligible patients receive #celltherapy. To overcome these barriers, everyone in the cell therapy space must work together – and always keep our focus on supporting patients and their physicians – as we aim to change the current landscape. This includes scaling manufacturing capacity to meet patient demand; developing a global network of treatment centers to bring therapies closer to patients; working on ways we can increase patient access; and coordinating the connections between oncologists and treatment centers to support each patient’s journey. #cgti

📚 In this Friday read, we spotlight a study published in Nature Communications aimed at increasing the efficacy of CAR T therapy by combining it with STING agonists. Researchers used the nCounter platform to analyze gene expression, revealing increased T cell activation and infiltration into tumors 👉https://lnkd.in/dM9a_SBM This combination improved survival and tumor control in models, presenting a promising strategy for enhancing CAR T therapy efficacy. #CARTherapy #CancerResearch #FridayRead

Do you work in cell and gene therapy and wonder how to integrate FDA-recommended cytokine secretion assays into your research? Join our free webinar on FluoroSpot in cell and gene therapy. We’ll cover: - the assay principles of ELISpot and FluoroSpot - their features and advantages over, for example, flow cytometry - use cases in which the assays have been utilized to gain functional data on CAR T cells, cancer vaccines, and others. Sign-up here: https://hubs.li/Q02yYlK20

If we look at Pharma, Cell and Gene Therapy, CAR-T, and Cancer Research, the upcoming solutions must be built on 3D cell culture. Considering the upcoming regulation of terminating all forms of animal testing for drugs, the only option left out would be shifting to 3D cell models like spheroids, organoid culture, and 3D bioprinting. Creating a cell culture model that can mimic the human microenvironment for organoid formation, stem cell scale-up, 2D coating, and smart cell delivery system is important. To achieve this, one of the most vital elements is to have the perfect EXTRACELLULAR MATRIX.

What's new this week in the #cellandgenetherapy sector? 🧠Early-stage CAR-T cell therapy demonstrates promising clinical activity for brain tumors 🧬New interim data for DMD gene therapy shows early evidence of strength and motor improvement Read the full stories below and subscribe to our Sector Vector newsletter for more weekly cell and gene therapy clinical, business, and manufacturing news: https://lnkd.in/eD7ZNaU Phase 1 clinical trial of a CAR-T cell therapy developed by City of Hope shows clinical activity in patients with aggressive brain tumors. https://lnkd.in/eSabcJWX REGENXBIO Inc. announced that the first patient at dose level 2 in their gene therapy trial to treat Duchenne muscular dystrophy demonstrated robust microdystrophin expression. It also observed early evidence of strength and motor function improvement. https://lnkd.in/etGeCa9S